Mimio Health has announced the publication of a randomized, double blind, placebo-controlled clinical trial in Nature Scientific Reports, which demonstrates the efficacy of the brand’s flagship fasting mimetic supplement.
The study revealed that when taken daily, the fasting mimetic supplement produced statistically significant improvements in total cholesterol, LDL cholesterol, LDL particle number, non-HDL cholesterol, oxidative stress, and fasting glucose compared to placebo. The innovation also showed improvements in appetite regulation, reducing hunger, food noise, and digestive discomfort. The formula does so by activating the same cellular pathways that are triggered during a 36-hour fast.
Mimio Health’s formulation uses a patented blend of human bioactives, including spermidine, nicotinamide, palmitoylethanolamide, and oleoylethanolamide, to mimic the metabolic, cellular, and longevity benefits of fasting without any change to how a person eats or lives.
Image Credit: Mimio Health
